ХЕРБСТ Роналд (US),УОРД Элизабет К. (US),МакКИВЕР Кэтлин Филлипс (US)
申请号：
RU2013127115/15
公开号：
RU2013127115A
申请日:
2011.11.14
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method of treating B-cell lymphoma comprising administering to a patient in need thereof a combination therapy comprising the antibody to CD19 and antibody to CD20, wherein said combination therapy provides an anti-tumor activity for a longer time than either said antibody to CD19, said antibody or to CD20, administered alone in a comparable dozirovaniya.2 mode. A method of treating B-cell lymphoma comprising administering to a patient in need thereof a combination therapy comprising the antibody to CD19 and antibody to CD20, wherein the dose of said combination therapy has stronger antitumor activity than the dose of said antibodies to CD19, which is at least twice the dose of the combined therapy.3. A method according to claim 1 or 2, wherein said B-cell lymphoma is selected from acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) or non-Hodgkins lymphoma (NHL) .4. The method of claim 1, wherein the combined therapy provides a synergistic therapeutic effekt.5. The method of claim 1 wherein the antibody to CD19 and to CD20 are administered together or posledovatelno.6. The method of claim 1, wherein the antitumor activity is selected from the group consisting of inhibition of tumor growth and depletion of neoplastic B kletok.7. The method of claim 1, wherein the combined therapy provides antitumor activity is at least six mesyatsev.8. The method of claim 1, wherein the combined therapy provides antitumor activity of at least one month longer, preferably at least six months longer than either said antibody against CD19, or the antibody to CD20, introduced by1. Способ лечения В-клеточной лимфомы, включающий введение пациенту, нуждающемуся в этом, комбинированной терапии, включающей антитело к CD19 и антитело к CD20, где указанная комбинированная терапия обеспечивает противоопухолевую активность более продолжительное время, чем либо указанное антитело к CD19, либо указанное антитело к CD20, введенные по отдельности в сопоставимом режиме дозиров
